Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that mimic the action of endogenous GLP-1, an incretin hormone secreted by intestinal L-cells in response to nutrient intake
Adopted by the hospitals Diversity, Equity, Inclusion & Belonging (DEIB) Council, the initiative aims to help people who have disabilities that are not immediately obvious, such as visual or hearing impairments, autism, chronic pain, dementia or anxiety
Standard clinical guidelines generally consider GLP-1 weight loss therapy for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia
This approach can lower the likelihood and seriousness of unwanted effects
OPRAH: It was hard MICHELLE: And in this brand culture, oh, itit drives me crazy